Ketamine shown to ease early postpartum depression symptoms after C-sections

Ketamine, the anesthetic and pain reliever that has been a fixture in operating rooms for decades, may have an unexpected second act: easing the early symptoms of depression that strike some women in the days immediately after a cesarean delivery. A meta-analysis of six randomized controlled trials, presented at the American Society of Anesthesiologists' 2026 annual meeting in San Diego, found that women who received ketamine or esketamine—a chemical variant of ketamine—during or shortly after a C-section showed measurably lower depressive symptoms in the first two weeks after birth compared to women who did not receive the drug.

The finding arrives at a moment when postpartum depression remains a significant public health concern. Roughly one in five women experience depression after giving birth, and the condition can ripple outward, affecting not only the mother's wellbeing but also her ability to bond with her newborn and the stability of her family. Cesarean delivery, which accounts for a substantial portion of births in developed countries, appears to carry particular risk: women recovering from surgical delivery show higher rates of early depressive symptoms—sadness, anxiety, irritability, a loss of interest in activities, difficulty connecting with the baby—than those who deliver vaginally. This vulnerability window, when a woman is simultaneously healing from major surgery and adjusting to the demands of a newborn, prompted researchers to ask whether medications already present in the operating room might offer protection.

The meta-analysis examined data from 1,832 women who underwent planned cesarean sections between January 2015 and September 2025. Researchers compared depressive symptom scores using the Edinburgh Postnatal Depression Scale, a standard screening tool administered between the third and fourteenth days after surgery. Women who received ketamine or esketamine showed what the researchers described as a small-to-moderate reduction in symptom scores—a standardized mean difference of negative 0.36—compared to the control group. The reduction was statistically significant, meaning it was unlikely to have occurred by chance alone.

Peter Hsin, a medical student at FIU Herbert Wertheim College of Medicine and the study's lead author, cautioned against reading too much into the results at this stage. The evidence suggests ketamine's benefits may extend beyond its established roles in anesthesia and pain management, he said, but it remains far too early to claim that the drug prevents clinically diagnosed postpartum depression or that it should become routine practice. The studies reviewed were relatively small, the follow-up periods brief, and critical questions remain unanswered: What is the optimal dose? When exactly should it be administered—during surgery or after? Does the early symptom reduction translate into sustained protection against full-blown postpartum depression months down the line?

Rose Berkun, an associate professor of anesthesiology at the University at Buffalo and a co-author of the analysis, outlined the next phase of investigation. Her team plans to conduct a prospective randomized trial within the Department of Anesthesiology at Buffalo, designed to evaluate whether ketamine administered during cesarean delivery can actually reduce both the incidence and severity of postpartum depression over a longer timeframe. That study will be essential: early symptom relief in the first two weeks is encouraging, but whether it prevents the condition from developing or worsening in the months that follow remains unknown. Until then, ketamine's role in the postpartum period remains promising but unproven—a possibility worth pursuing, not yet a solution ready for widespread adoption.